- COVID-19 has increased the need for disposable neurological technology
- Currently no way exists to ensure electrodes are free of contamination when using traditional reusable EEGs
- Neurological manifestations have presented themselves in 82% of hospitalized COVID-19
Brain Scientific (OTCQB: BRSF) is a commercial-stage, health-care company modernizing the brain diagnostic market through cutting-edge technologies. The company is fulfilling a growing need for improved brain monitoring that is cost efficient, disposable and portable. Neurological conditions are on the rise, increasing the need for an already sparse supply of specialized neurologists.
COVID-19 has increased the need for disposable neurological technology that is accessible to all. Traditional reusable EEG electrodes, even when cleaned, may still have microscopic traces of bacteria.
“Even when we follow all aspects of high-level disinfecting for our reusable products, there are so many nooks and crannies on the electrodes that there is no way to ensure that an electrode is completely free of any risk of contamination,” says Leah Hanson, R.EEG/EP T, vice president of global sales and marketing at Rhythmlink International, a medical equipment manufacturer (https://ibn.fm/1F1O8).
When combating a highly contagious disease, disposable technology ensures that the virus is not spread through equipment. Brain Scientific’s single-use, disposable EEG caps also shorten person-to-person contact due to ease of placement, decreasing transmission between staff and patient.
“As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly and safely assess neurological changes in these patients,” wrote Brain Scientific co-founder and executive chairman Boris Goldstien in a recent “Pharma Mirror” article (https://ibn.fm/eMaUx). “Disposable EEG headsets are a cost-effective, readily-available solution that can be adopted for widespread use in these facilities during the current pandemic and moving forward to help healthcare workers gain a quick, reliable picture of a patient’s condition and receive treatment insights”
COVID-19 has also increased the need for neurological studies and long-term care. Neurological manifestations have presented themselves in 82% of hospitalized COVID-19 patients during the disease course. With a shortage of neurologists and accredited EEG technicians, the gap for needed medical care is widening. Brain Scientific’s disposable EEG’s provide an efficient means to collect results. Set-up takes roughly five minutes, compared to the 45-minute set-up of traditional sensors and does not require a skilled technician. Nurse practitioners, physicians and staff can administer the test.
Now that the virus has been in known existence for more than a year, studies are beginning to emerge describing long-term effects, including cognitive impairment lingering. A study conducted in Italy saw one-third of patients hospitalized with COVID-19 presenting abnormalities on neurologic exams six months later. These abnormalities included cognitive deficits, hyposmia, postural tremors, fatigue, memory impairment, depression/anxiety and sleep disorders (https://ibn.fm/TXZZ4).
More long-term studies are needed to fully understand the impact of COVID-19 on the brain.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
